Stock ALPHA PHARNEXT SCA
Add to a list
To use this feature you must be a member
Log inSign up

Pharnext SCA Share Price

Equities

ALPHA

FR001400N1P4

Pharmaceuticals

Market Closed - Euronext Paris
Other stock markets
 16:35:00 26/04/2024 BST 		5-day change 1st Jan Change
0.1499 EUR -8.88% Intraday chart for Pharnext SCA -12.75% -92.50%
04-25 Pharnext: share price rises on encouraging comments CF
03-06 Pharnext: listing suspended pending further update CF

Financials

Sales 2021 3.56M 3.81M 305M Sales 2022 2.26M 2.41M 193M Capitalization 26.02K 27.82K 2.23M
Net income 2021 -30M -32.08M -2.57B Net income 2022 -38M -40.63M -3.25B EV / Sales 2021 -
Net Debt 2021 14.24M 15.22M 1.22B Net Debt 2022 22.16M 23.69M 1.9B EV / Sales 2022 -
P/E ratio 2021 *
-
P/E ratio 2022
-
Employees 23
Yield 2021 *
-
Yield 2022
-
Free-Float 99%
More Fundamentals * Assessed data

Chart Pharnext SCA

Dynamic Chart

Latest news about Pharnext SCA

Pharnext: share price rises on encouraging comments CF
Pharnext: listing suspended pending further update CF
Global markets live: BAE Systems, HSBC, Nvidia, Tesla, Boeing... Our Logo
Pharnext SA announced that it has received ?41.188458 million in funding CI
Pharnext launches drastic cost-cutting plan CF
Pharnext Unveils Cost Reduction Plan, to Continue Development of Neurological Disorder Drug MT
Pharnext: registration dossiers prepared for Charcot disease CF
Pharnext: share price falls after disappointing clinical study CF
Pharnext SA announced that it expects to receive ?1.5 million in funding CI
Pharnext: phase III study data frozen CF
Pharnext Delays Exclusivity Agreement for Peripheral Nerve Disease Drug; Shares Sink MT
Pharnext: fundraising, new trading calendar CF
Pharnext: Phase III results expected on December 11 CF
Pharnext: share price rises, milestone achieved in the USA CF
Pharnext Manufactures US Registration Batches of Oral Solution Ahead of FDA Application MT
More news

Press releases Pharnext SCA

Pharnext Sca : Pharnext takes full stock of its operating, strategic and financial situation AT
Pharnext : Présentation corporate de Pharnext PU
Pharnext Sca : Pharnext progresses in analyzing data from pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1A AT
Pharnext Sca : Pharnext commits to a drastic cost-cutting plan and receives support from its financial partners to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1A AT
Pharnext Sca : Pharnext commits to a drastic cost-cutting plan to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1A AT
More press releases

News in other languages on Pharnext SCA

Pharnext : le titre grimpe sur des propos encourageants
Pharnext : a présenté les données de l'étude pivot de Phase III de PXT3003 dans la maladie de Charcot-Marie-Tooth de type 1A au congrès annuel de CMT-France
Pharnext Sca : Pharnext a présenté les données de l’étude pivot de Phase III de PXT3003 dans la maladie de Charcot-Marie-Tooth de type 1A au congrès annuel de CMT-France
Pharnext Sca : Ajustement de la valeur nominale
Pharnext : Ajustement de la valeur nominale (French version only)
More news

Quotes and Performance

1 day-8.88%
1 week-12.75%
Current month-40.04%
1 month-47.39%
3 months-85.01%
6 months-99.96%
Current year-92.50%
More quotes

Highs and lows

1 week
0.14
Extreme 0.136
0.22
1 month
0.12
Extreme 0.1201
0.30
Current year
0.12
Extreme 0.1201
3.00
1 year
0.12
Extreme 0.1201
1 000 000.00
3 years
0.12
Extreme 0.1201
1 000 000.00
5 years
0.12
Extreme 0.1201
1 000 000.00
10 years
0.12
Extreme 0.1201
1 000 000.00
More quotes

Managers and Directors - Pharnext SCA

Managers TitleAgeSince
Hugo Brugière CEO
 Chief Executive Officer - 07/11/22
Serguei Nabirotchkine FOU
 Founder - 31/12/06
Melissa Israel CTO
 Chief Tech/Sci/R&D Officer - 30/11/20
Members of the board TitleAgeSince
James Kuo BRD
 Director/Board Member 58 15/06/22
Lawrence Steinman BRD
 Director/Board Member 76 16/07/20
Guy-Charles Fanneau de la Horie BRD
 Director/Board Member 64 09/07/23
More insiders

Quotes

Date Price Change Volume
26/04/24 0.1499 -8.88% 81,812
25/04/24 0.1645 +17.50% 311,583
24/04/24 0.14 -7.47% 16,096
23/04/24 0.1513 -15.90% 18,354
22/04/24 0.1799 +4.71% 39,136

Real-time Euronext Paris, April 26, 2024 at 04:35 pm

More quotes

Company Profile

Pharnext SCA specializes in the development of drugs based on PleotherapyTM for the treatment of severe, rare and common neurological diseases (including Alzheimer, Charcot-Marie Tooth disease, Parkinson's and amyotrophic lateral sclerosis). The company keeps creating new treatments by combining, at very low doses, molecules that are already tested for other diseases. The group has a portfolio of 2 products in clinical development: PXT3003 (treatment of the orphan disease Charcot-Marie-Tooth type 1A) and PXT864 (Alzheimer's disease treatment).
Sector
Pharmaceuticals
Calendar
16/10/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
PHARNEXT SCA Stock Pharnext SCA
-92.50% 27.82K
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ALPHA Stock